NCT07801547Not yet recruiting
Muscle Oxygenation in Patients With COPD Exacerbation
Evaluation of Respiratory and Peripheral Muscle Oxygenation in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
Chronic obstructive pulmonary disease (COPD) is often complicated by acute exacerbations, which lead to functional impairments, increased dyspnea, and a rapid decline in lung function. During an exacerbation, impaired pulmonary gas exchange, systemic inflammation, and increased work of breathing significantly alter oxygen availability and metabolic demand in skeletal muscles. The aim of this study is to evaluate and compare respiratory and peripheral muscle oxygenation in patients with acute exacerbation of COPD (AECOPD) and patients with clinically stable COPD. By examining these physiological changes, the study seeks to determine the impact of exacerbations on muscle function and oxygenation efficiency
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 28 Aug 2026
- Start date
- 30 Aug 2026
- Primary completion date
- 5 Oct 2027
- Lead sponsor
- Hacettepe University
- Diseases
- COPD
- NCT number
- NCT07801547
What you commit to
- Study type: Observational
- Planned participants: 40
- From 30 Aug 2026 to the primary completion date, 5 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Clinically Stable Group: 1. History of lung cancer, sarcoidosis, tuberculosis, and/or prior lung surgery 2. Known mental or cognitive impairment.
Who the study is looking for
- Acute Exacerbation Group: 1. Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) 2. Hospital admission or presentation due to an acute exacerbation of COPD 3. Age 40 years or older 4. Voluntary agreement to participate with signed written informed consent Clinically Stable Group: 1. Diagnosis of COPD (GOLD Stage 1, 2, 3, or 4) 2. Age 40 years or older 3. Clinically stable condition for at least the past 4 weeks without acute exacerbations 4. Voluntary agreement to participate with signed written informed consent
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hacettepe University Coordinator of this site? Confirm its status | Ankara | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.